The trial was conducted across 11 sites in seven sub-Saharan African countries. It has shown that giving three doses of RTS,S/AS01 to children aged 5 to 17 months, reduced the risk of the child experiencing clinical malaria and severe malaria by 56% and 47% respectively. The results come from the first 6,000 children of 8,923 in this age category. Results for younger children, vaccinated at 6 to 12 weeks of age, in addition to formal analysis of vaccine efficacy against death will be available as the study continues. The results from this study could prove to be highly valuable in the continuing fight against malaria.
Agnandji et al. First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N Engl J Med. 2011 Nov 17;365(20):1863-75. doi: 10.1056/NEJMoa1102287. Epub 2011 Oct 18.
White. A vaccine for malaria. N Engl J Med. 2011 Nov 17;365(20):1926-7. doi: 10.1056/NEJMe1111777. Epub 2011 Oct 18.